DUBLIN--(BUSINESS WIRE)--The "Global Induced Pluripotent Stem Cells Market: 2021-2026" report has been added to ResearchAndMarkets.com's offering.
This study focuses on the market side of iPSCs rather than its technical side. Different market segments for this emerging market are covered.
Product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis. Application-based market segments include drug development and toxicity testing, academic research, and regenerative medicine. iPSC-derived cell-type-based market segments include hepatocytes, neurons, cardiomyocytes, endothelial cells, and other cell types.
Other cell types are comprised of astrocytes, fibroblasts, hematopoietic progenitor cells, etc. Geographical-based market segments include the U.S., Asia-Pacific, Europe, and the Rest of the World. The research and market trends are also analyzed by studying the funding, patent publications and research publications in the field.
This report focuses on the market size and segmentation of iPSC products, including iPSC research and clinical products. The market for iPSC-related contract services is also discussed. iPSC research products are defined as all research tools, including iPSCs and various differentiated cells derived from iPSCs, various related assays and kits, culture media and medium components (e.g., serum, growth factors, inhibitors), antibodies, enzymes, and products that can be applied for the specific purpose of executing iPSC research. For this report, iPSC products do not cover stem cell research and clinical products, which are broadly applicable to any stem cell type.
This report discusses key manufacturers, technologies and factors influencing market demand, including the driving forces and limiting factors of the iPSCs market growth. Based on these facts and analysis, the market trends and sales for research and clinical applications are forecast through 2026.
One particular focus on the application of iPSCs was given to drug discovery and development, which includes pharmaco-toxicity screening, lead generation, target identification, and other preclinical studies, body-on-a-chip, and 3D disease modeling. Suppliers and manufacturers of iPSC-related products are discussed and analyzed based on their market shares, product types, and geography. An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSCs market.
The detailed technologies such as those for generating iPSCs, differentiating iPSCs, controlling the differentiation, and large-scale manufacturing of iPSCs and their derivative cells under GMP compliance or xeno-free conditions are excluded from the study, as they are beyond the scope of this report.
The Report Includes:
- An updated review of the global market for induced pluripotent stem cells (iPSC) within the industry
- Analyses of the global market trends, with data from 2020, estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
- Estimation of the market size and revenue forecast for the iPSCs market, and corresponding market share analysis by market segments such as application, reprogramming method, iPSCs generation method, product function and geography
- Highlights of emerging technology trends, market opportunities and deterrents estimating current and future demand of iPSC-related products and their derivatives for drug discovery
- Identification of the companies that are best positioned to meet this demand because of their proprietary technologies, strategic alliances, or other advantages
- Discussion of market dynamics that impact the growth of the market for iPSCs, clinical applications, market regulations, industry structure, and penetration of technologies within the biotech industry
- Insight into the segmentation of iPSC products, including iPSC research and clinical products, along with application-based segments such as academic research, drug development and regenerative medicine as well as iPSC-related contract services
- Number of global (+ the U.S.) patents and patent applications on induced pluripotent stem cells, and corresponding iPSC scientific publications during the period of 2008-October 2019
- Competitive landscape of the key manufacturers and suppliers in the iPSC market, their competitive environment and major growth strategies within the global market
- Descriptive company profiles of leading industry players, including Applied Biological Materials Inc., Bristol-Myers Squibb, Corning Inc., Merck KGaA and Thermo Fisher Scientific
Companies Mentioned
- Addgene
- Allele Biotechnology And Pharmaceuticals Inc.
- ATCC
- Bio-Techne
- Bluerock Therapeutics
- Bristol-Myers Squibb (Ipierian)
- Cell Signaling Technology (Cst)
- Corning Inc.
- Creative Bioarray
- Fate Therapeutics
- Genecopoeia
- Gentarget Inc.
- ID Pharma Co., Ltd.
- Invivogen
- Lonza Group Ltd.
- Megakaryon Corp.
- Merck Kgaa
- Mti-Globalstem, A Part Of Thermo Fisher Scientific
- Ncardia
- Newcells Biotech
- Peprotech
- Plasticell Ltd.
- Promega Corp.
- Promocell Gmbh
- Qiagen N.V.
- Reprocell Inc.
- Sciencell Research Laboratories
- Stemcell Technologies
- System Biosciences Inc.
- Takara Bio Usa Inc. (Clontech Laboratories)
- Thermo Fisher Scientific
- Viacyte Inc.
- Waisman Biomanufacturing
For more information about this report visit https://www.researchandmarkets.com/r/lggd63
